An Open Label Multi-Centre Preoperative Window of Opportunity Study of Afatinib in Stage Ia to IIb Non-Small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 14 Nov 2017
At a glance
- Drugs Afatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacodynamics
- Acronyms ABLE
- 10 Jun 2017 Biomarkers information updated
- 17 Sep 2015 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials record.
- 15 Aug 2015 Accrual to date is 6 % according to United Kingdom Clinical Research Network record.